{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,7]],"date-time":"2026-05-07T09:43:57Z","timestamp":1778147037900,"version":"3.51.4"},"reference-count":16,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,4,14]],"date-time":"2021-04-14T00:00:00Z","timestamp":1618358400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2021,4,14]],"date-time":"2021-04-14T00:00:00Z","timestamp":1618358400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Psychiatry"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Although long-term use of benzodiazepines and benzodiazepine receptor agonists (BZDs) has been associated with an increased risk of dependence, the incidence, details of clinical manifestations, and triggering factors of withdrawal symptoms associated with long-term BZD use at common clinical doses remain unclear.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>In a multicenter, open-label study of 123 Japanese patients with insomnia, patients were given a common clinical dose of eszopiclone (2\u2009mg) for 24\u2009weeks, and then treatment was abruptly discontinued. Withdrawal symptoms were evaluated using the Benzodiazepine Hypnotics Withdrawal Symptom Scale (BHWSS). The Insomnia Severity Index (ISI) was used to rate insomnia severity during treatment and 2\u2009weeks after discontinuation. Dependence and poor compliance during treatment without strict medication controls were evaluated with the Benzodiazepine Dependence Self Report Questionnaire short version (Bendep-SRQ SV) subscale sum scores for problematic use, preoccupation, and lack of compliance. Associations between the presence of clinically relevant withdrawal symptoms (BHWSS\u22657) and demographic measures, ISI scores at Week 24, and Bendep-SRQ SV subscale sum scores were evaluated by multivariable stepwise logistic regression analyses.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Seventy-six patients completed treatment and 2\u2009weeks of withdrawal; eight (10.5%) had clinically relevant withdrawal symptoms. On multiple logistic regression analysis, Bendep-SRQ SV subscale sum scores were correlated with withdrawal symptoms (odds ratio, 1.650; 95% confidence interval, 1.105\u20132.464; <jats:italic>p<\/jats:italic>\u2009=\u20090.014). Exacerbation of post-discontinuation insomnia was not significantly different between patients who showed clinically relevant withdrawal symptoms and those who did not (<jats:italic>p<\/jats:italic>\u2009=\u20090.245).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>Dependence and poor compliance may contribute to withdrawal symptoms with long-term BZD use. Providing guidance to ensure proper compliance is thought to be the best way to mitigate withdrawal symptoms.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Trial registration<\/jats:title>\n                <jats:p><jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"https:\/\/rctportal.niph.go.jp\/en\/detail?trial_id=UMIN000024462\">UMIN000024462<\/jats:ext-link> (18\/10\/2016).<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12888-021-03196-0","type":"journal-article","created":{"date-parts":[[2021,4,14]],"date-time":"2021-04-14T05:04:46Z","timestamp":1618376686000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Prevalence of and factors associated with acute withdrawal symptoms after 24\u2009weeks of eszopiclone treatment in patients with chronic insomnia: a prospective, interventional study"],"prefix":"10.1186","volume":"21","author":[{"given":"Yuichi","family":"Inoue","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshikazu","family":"Takaesu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michinori","family":"Koebis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,4,14]]},"reference":[{"issue":"2","key":"3196_CR1","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1176\/appi.ps.201700095","volume":"69","author":"CN Kaufmann","year":"2018","unstructured":"Kaufmann CN, Spira AP, Depp CA, Mojtabai R. Long-term use of benzodiazepines and nonbenzodiazepine hypnotics, 1999\u20132014. Psychiatr Serv. 2018;69(2):235\u20138. https:\/\/doi.org\/10.1176\/appi.ps.201700095.","journal-title":"Psychiatr Serv"},{"key":"3196_CR2","unstructured":"National Federation of Health Insurance Societies. Survey III of Insurance Billing Records to Inform Policy Formulation. Available at https:\/\/www.kenporen.com\/include\/outline\/pdf\/chosa29_01-2.pdf. Accessed 31 Jan 2020."},{"issue":"12","key":"3196_CR3","doi-asserted-by":"publisher","first-page":"1147","DOI":"10.1056\/NEJMra1611832","volume":"376","author":"M Soyka","year":"2017","unstructured":"Soyka M. Treatment of benzodiazepine dependence. N Engl J Med. 2017;376(12):1147\u201357. https:\/\/doi.org\/10.1056\/NEJMra1611832.","journal-title":"N Engl J Med"},{"issue":"3","key":"3196_CR4","doi-asserted-by":"publisher","first-page":"958","DOI":"10.1016\/j.psychres.2015.11.003","volume":"230","author":"A Murakoshi","year":"2015","unstructured":"Murakoshi A, Takaesu Y, Komada Y, Ishikawa J, Inoue Y. Prevalence and associated factors of hypnotics dependence among Japanese outpatients with psychiatric disorders. Psychiatry Res. 2015;230(3):958\u201363. https:\/\/doi.org\/10.1016\/j.psychres.2015.11.003.","journal-title":"Psychiatry Res"},{"issue":"7","key":"3196_CR5","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1093\/sleep\/26.7.793","volume":"26","author":"AD Krystal","year":"2003","unstructured":"Krystal AD, Walsh JK, Laska E, Caron J, Amato DA, Wessel TC, et al. Sustained efficacy of eszopiclone over 6 months of nightly treatment: results of a randomized, double-blind, placebo-controlled study in adults with chronic insomnia. Sleep. 2003;26(7):793\u20139. https:\/\/doi.org\/10.1093\/sleep\/26.7.793.","journal-title":"Sleep"},{"issue":"8","key":"3196_CR6","doi-asserted-by":"publisher","first-page":"959","DOI":"10.1093\/sleep\/30.8.959","volume":"30","author":"JK Walsh","year":"2007","unstructured":"Walsh JK, Krystal AD, Amato DA, Rubens R, Caron J, Wessel TC, et al. Nightly treatment of primary insomnia with eszopiclone for six months: effect on sleep, quality of life, and work limitations. Sleep. 2007;30(8):959\u201368. https:\/\/doi.org\/10.1093\/sleep\/30.8.959.","journal-title":"Sleep"},{"issue":"6","key":"3196_CR7","doi-asserted-by":"publisher","first-page":"706","DOI":"10.1111\/j.1600-0447.1988.tb06408.x","volume":"78","author":"D Schneider-Helmert","year":"1988","unstructured":"Schneider-Helmert D. Why low-dose benzodiazepine-dependent insomniacs can\u2019t escape their sleeping pills. Acta Psychiatr Scand. 1988;78(6):706\u201311. https:\/\/doi.org\/10.1111\/j.1600-0447.1988.tb06408.x.","journal-title":"Acta Psychiatr Scand"},{"issue":"8","key":"3196_CR8","doi-asserted-by":"publisher","first-page":"1179","DOI":"10.1046\/j.1360-0443.1996.91811799.x","volume":"91","author":"H Mart\u00ednez-Cano","year":"1996","unstructured":"Mart\u00ednez-Cano H, Vela-Bueno A, De Iceta M, Pomalima R, Mart\u00ednez-Gras I, Sobrino MP. Benzodiazepine types in high versus therapeutic dose dependence. Addiction. 1996;91(8):1179\u201386. https:\/\/doi.org\/10.1046\/j.1360-0443.1996.91811799.x.","journal-title":"Addiction"},{"issue":"1-2","key":"3196_CR9","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/0740-5472(91)90024-5","volume":"8","author":"U Busto","year":"1991","unstructured":"Busto U, Sellers EM. Pharmacologic aspects of benzodiazepine tolerance and dependence. J Subst Abus Treat. 1991;8(1-2):29\u201333. https:\/\/doi.org\/10.1016\/0740-5472(91)90024-5.","journal-title":"J Subst Abus Treat"},{"issue":"3","key":"3196_CR10","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1097\/01.yco.0000165594.60434.84","volume":"18","author":"H Ashton","year":"2005","unstructured":"Ashton H. The diagnosis and management of benzodiazepine dependence. Curr Opin Psychiatry. 2005;18(3):249\u201355. https:\/\/doi.org\/10.1097\/01.yco.0000165594.60434.84.","journal-title":"Curr Opin Psychiatry"},{"key":"3196_CR11","volume-title":"The International Classification of Sleep Disorders, Third Edition (ICSD-3)","author":"American Academy of Sleep Medicine","year":"2014","unstructured":"American Academy of Sleep Medicine. The International Classification of Sleep Disorders, Third Edition (ICSD-3). 2014."},{"key":"3196_CR12","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1007\/s41105-018-0151-0","volume":"16","author":"M Kobayashi","year":"2018","unstructured":"Kobayashi M, Okajima I, Narisawa H, Kikuchi T, Matsui K, Inada K, et al. Development of a new benzodiazepine hypnotics withdrawal symptom scale. Sleep Biol Rhythms. 2018;16:63\u2013271.","journal-title":"Sleep Biol Rhythms"},{"issue":"4","key":"3196_CR13","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1016\/S0010-440X(99)90129-3","volume":"40","author":"CC Kan","year":"1999","unstructured":"Kan CC, Breteler MH, Timmermans EA, van der Ven AH, Zitman FG. Scalability, reliability, and validity of the benzodiazepine dependence self-report questionnaire in outpatient benzodiazepine users. Compr Psychiatry. 1999;40(4):283\u201391. https:\/\/doi.org\/10.1016\/S0010-440X(99)90129-3.","journal-title":"Compr Psychiatry"},{"issue":"5","key":"3196_CR14","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1093\/sleep\/34.5.601","volume":"34","author":"CM Morin","year":"2011","unstructured":"Morin CM, Belleville G, B\u00e9langer L, Ivers H. The insomnia severity index: psychometric indicators to detect insomnia cases and evaluate treatment response. Sleep. 2011;34(5):601\u20138. https:\/\/doi.org\/10.1093\/sleep\/34.5.601.","journal-title":"Sleep"},{"issue":"5","key":"3196_CR15","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1053\/comp.2001.26276","volume":"42","author":"CC Kan","year":"2001","unstructured":"Kan CC, van der Ven AH, Breteler MHM, Zitman FG. Latent trait standardization of the benzodiazepine dependence self-report questionnaire using the Rasch scaling model. Compr Psychiatry. 2001;42(5):424\u201332. https:\/\/doi.org\/10.1053\/comp.2001.26276.","journal-title":"Compr Psychiatry"},{"key":"3196_CR16","doi-asserted-by":"publisher","first-page":"832","DOI":"10.1016\/B978-0-323-24288-2.00087-8","volume-title":"Principles and practice of sleep medicine (sixth edition).","author":"JK Walsh","year":"2017","unstructured":"Walsh JK, Roth T. Chapter 87\u2014pharmacologic treatment of insomnia: benzodiazepine receptor agonists. In: Kryger M, Roth T, Dement WC, editors. Principles and practice of sleep medicine (sixth edition). Philadelphia: Elsevier; 2017. p. 832\u2013841.e4."}],"container-title":["BMC Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12888-021-03196-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12888-021-03196-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12888-021-03196-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,4,14]],"date-time":"2021-04-14T05:06:30Z","timestamp":1618376790000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcpsychiatry.biomedcentral.com\/articles\/10.1186\/s12888-021-03196-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4,14]]},"references-count":16,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["3196"],"URL":"https:\/\/doi.org\/10.1186\/s12888-021-03196-0","relation":{},"ISSN":["1471-244X"],"issn-type":[{"value":"1471-244X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,4,14]]},"assertion":[{"value":"29 October 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 March 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 April 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study protocol and all amendments were approved by the ethics committees of the Institute of Neuropsychiatry. The study was also conducted in compliance with the Declaration of Helsinki and \u201cEthical Guidelines for Medical and Health Research Involving Human Subjects.\u201d Written informed consent to participate in the study was obtained for all participants.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"YI reports research funding from Eisai Co., Ltd. during the conduct of the study; personal fees and honoraria from Pacific Medico Co., Ltd., Otsuka Pharmaceutical Co., Ltd., and MSD K.K.; grants, personal fees, honoraria, and research funding from Takeda Pharmaceutical Co., Ltd., Eisai Co., Ltd., Alfresa Pharma Corporation, Koike Medical Co., Ltd., and Koninklijke Philips N.V.; personal fees, honoraria and clinical trial funding from Astellas Pharma Inc.; and clinical trial funding from Janssen Pharmaceutical K.K. and Idorsia Pharma Inc., outside the submitted work. YT reports grants and personal fees from Otsuka Pharmaceutical Co., Ltd., Meiji Seika Pharma Co., Ltd., MSD K.K., Eisai Co., Ltd., and Takeda Pharmaceutical Company Limited; and personal fees from Eli Lilly and Company, Mitsubishi Tanabe Pharma Corporation, and Yoshitomi Pharmaceutical Industries, Ltd., outside the submitted work. MK is an employee of Eisai Co., Ltd.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"193"}}